

## Shionogi has been Selected for the ESG Investment Index “FTSE Blossom Japan Sector Relative Index” Adopted by GPIF

**OSAKA, Japan, April 8, 2022** - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi has been included in the "FTSE Blossom Japan Sector Relative Index".

“FTSE Blossom Japan Sector Relative Index” was developed by global index provider FTSE Russell. It is designed to measure the performance of Japanese companies that demonstrate strong Environmental, Social and Governance (ESG) practices using a sector-neutral approach which minimizes sector bias. It also supports climate transition to a low carbon economy by evaluating companies’ climate governance and efforts with the TPI Management quality score <sup>1)</sup>.



**FTSE Blossom  
Japan Sector  
Relative Index**

1) Scores assessing the quality of management of opportunities and risks associated with a company's greenhouse gas emissions and transition to low carbon by the Transition Pathway Initiative (TPI)

In our medium-term business plan, STS2030, Shionogi has identified its material issues, and set forth its efforts to achieve the SDGs, through its business activities which include protecting people worldwide from the threat of infectious diseases and contributing to the realization of a sustainable society. At the same time, we are committed to pursuing and reinforcing our responses to ESGs, supporting sustainability and driving the company’s growth. Based on this commitment, Shionogi will make a concerted effort to benefit all of its stakeholder groups well into the future.

For Further Information, Contact:

SHIONOGI Website Inquiry Form : <https://www.shionogi.com/global/en/contact.html>

### Forward-Looking Statements

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials;*

# Press Release



*obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*